Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia

Jennifer Smith, Rolando Herrero, Kerstin Erles, Dirk Grimm, Nubia Muñoz, F. Xavier Bosch, Luis Tafur, Keerti V. Shah, Jörg R. Schlehofer

Research output: Contribution to journalArticle

Abstract

Extensive experimental and limited epidemiologic data suggest that adeno-associated viruses (AAV) can have anti-oncogenic activity and may be protective factors for the development of cervical cancer. To examine the association between AAV-2 IgG antibodies and cervical neoplasia in Spain and Colombia, we tested for AAV-2 antibodies using an ELISA assay for 109 women with invasive cervical cancer, 100 population-based controls age-matched to the invasive cases, 77 women with carcinoma in situ (CIN III) and 100 clinic-based controls age-matched to the CIN III cases. Human papillomavirus (HPV) DNA was detected in cervical exfoliated cells by polymerase chain reaction using HPV-L1 and GP5+/6+ consensus primers. The prevalence of AAV-2 antibody titers > 100 was significantly lower in invasive cervical cancer cases than control participants. When comparing women with invasive cancer with controls or with CIN III cases, a pattern of decreasing cervical cancer risk with increasing AAV-2 titers was observed. Elevated AAV antibody titers (> 100) were inversely associated with invasive cervical cancer (OR 0.3; 95% Cl 0.1-0.7), although results were not statistically significant after controlling for HPV (OR 0.4; 95% Cl 0.1-1.6). In contrast, AAV-2 antibodies were not significantly associated with the risk of CIN III (OR 1.4; 95% Cl 0.3-6.8). These results provide supportive evidence that AAV infection may be a protective factor for the development of invasive cervical cancer. Alternatively, the lower AAV-2 seroprevalence in invasive cervical cancer cases may be due to an immunosuppressive effect of cervical cancer on AAV antibody response. To investigate whether a direct viral interaction is occurring, future studies should aim to resolve at what frequency AAV is found in the genital tract and to clarify further whether AAV may infect the same HPV-positive cells in the cervix.

Original languageEnglish (US)
Pages (from-to)520-526
Number of pages7
JournalInternational Journal of Cancer
Volume94
Issue number4
DOIs
StatePublished - Nov 15 2001

Fingerprint

Dependovirus
Colombia
Uterine Cervical Neoplasms
Spain
Antibodies
Viral Load
Population Control
Carcinoma in Situ
Seroepidemiologic Studies
Virus Diseases
Immunosuppressive Agents
Cervix Uteri
Antibody Formation
Neoplasms
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay

Keywords

  • Adeno-associated viruses
  • Cervical cancer
  • Etiology
  • HPV cofactors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Smith, J., Herrero, R., Erles, K., Grimm, D., Muñoz, N., Bosch, F. X., ... Schlehofer, J. R. (2001). Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. International Journal of Cancer, 94(4), 520-526. https://doi.org/10.1002/ijc.1496

Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. / Smith, Jennifer; Herrero, Rolando; Erles, Kerstin; Grimm, Dirk; Muñoz, Nubia; Bosch, F. Xavier; Tafur, Luis; Shah, Keerti V.; Schlehofer, Jörg R.

In: International Journal of Cancer, Vol. 94, No. 4, 15.11.2001, p. 520-526.

Research output: Contribution to journalArticle

Smith, J, Herrero, R, Erles, K, Grimm, D, Muñoz, N, Bosch, FX, Tafur, L, Shah, KV & Schlehofer, JR 2001, 'Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia', International Journal of Cancer, vol. 94, no. 4, pp. 520-526. https://doi.org/10.1002/ijc.1496
Smith, Jennifer ; Herrero, Rolando ; Erles, Kerstin ; Grimm, Dirk ; Muñoz, Nubia ; Bosch, F. Xavier ; Tafur, Luis ; Shah, Keerti V. ; Schlehofer, Jörg R. / Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. In: International Journal of Cancer. 2001 ; Vol. 94, No. 4. pp. 520-526.
@article{f683085d89b2482ca842d6acae1f6f9e,
title = "Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia",
abstract = "Extensive experimental and limited epidemiologic data suggest that adeno-associated viruses (AAV) can have anti-oncogenic activity and may be protective factors for the development of cervical cancer. To examine the association between AAV-2 IgG antibodies and cervical neoplasia in Spain and Colombia, we tested for AAV-2 antibodies using an ELISA assay for 109 women with invasive cervical cancer, 100 population-based controls age-matched to the invasive cases, 77 women with carcinoma in situ (CIN III) and 100 clinic-based controls age-matched to the CIN III cases. Human papillomavirus (HPV) DNA was detected in cervical exfoliated cells by polymerase chain reaction using HPV-L1 and GP5+/6+ consensus primers. The prevalence of AAV-2 antibody titers > 100 was significantly lower in invasive cervical cancer cases than control participants. When comparing women with invasive cancer with controls or with CIN III cases, a pattern of decreasing cervical cancer risk with increasing AAV-2 titers was observed. Elevated AAV antibody titers (> 100) were inversely associated with invasive cervical cancer (OR 0.3; 95{\%} Cl 0.1-0.7), although results were not statistically significant after controlling for HPV (OR 0.4; 95{\%} Cl 0.1-1.6). In contrast, AAV-2 antibodies were not significantly associated with the risk of CIN III (OR 1.4; 95{\%} Cl 0.3-6.8). These results provide supportive evidence that AAV infection may be a protective factor for the development of invasive cervical cancer. Alternatively, the lower AAV-2 seroprevalence in invasive cervical cancer cases may be due to an immunosuppressive effect of cervical cancer on AAV antibody response. To investigate whether a direct viral interaction is occurring, future studies should aim to resolve at what frequency AAV is found in the genital tract and to clarify further whether AAV may infect the same HPV-positive cells in the cervix.",
keywords = "Adeno-associated viruses, Cervical cancer, Etiology, HPV cofactors",
author = "Jennifer Smith and Rolando Herrero and Kerstin Erles and Dirk Grimm and Nubia Mu{\~n}oz and Bosch, {F. Xavier} and Luis Tafur and Shah, {Keerti V.} and Schlehofer, {J{\"o}rg R.}",
year = "2001",
month = "11",
day = "15",
doi = "10.1002/ijc.1496",
language = "English (US)",
volume = "94",
pages = "520--526",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia

AU - Smith, Jennifer

AU - Herrero, Rolando

AU - Erles, Kerstin

AU - Grimm, Dirk

AU - Muñoz, Nubia

AU - Bosch, F. Xavier

AU - Tafur, Luis

AU - Shah, Keerti V.

AU - Schlehofer, Jörg R.

PY - 2001/11/15

Y1 - 2001/11/15

N2 - Extensive experimental and limited epidemiologic data suggest that adeno-associated viruses (AAV) can have anti-oncogenic activity and may be protective factors for the development of cervical cancer. To examine the association between AAV-2 IgG antibodies and cervical neoplasia in Spain and Colombia, we tested for AAV-2 antibodies using an ELISA assay for 109 women with invasive cervical cancer, 100 population-based controls age-matched to the invasive cases, 77 women with carcinoma in situ (CIN III) and 100 clinic-based controls age-matched to the CIN III cases. Human papillomavirus (HPV) DNA was detected in cervical exfoliated cells by polymerase chain reaction using HPV-L1 and GP5+/6+ consensus primers. The prevalence of AAV-2 antibody titers > 100 was significantly lower in invasive cervical cancer cases than control participants. When comparing women with invasive cancer with controls or with CIN III cases, a pattern of decreasing cervical cancer risk with increasing AAV-2 titers was observed. Elevated AAV antibody titers (> 100) were inversely associated with invasive cervical cancer (OR 0.3; 95% Cl 0.1-0.7), although results were not statistically significant after controlling for HPV (OR 0.4; 95% Cl 0.1-1.6). In contrast, AAV-2 antibodies were not significantly associated with the risk of CIN III (OR 1.4; 95% Cl 0.3-6.8). These results provide supportive evidence that AAV infection may be a protective factor for the development of invasive cervical cancer. Alternatively, the lower AAV-2 seroprevalence in invasive cervical cancer cases may be due to an immunosuppressive effect of cervical cancer on AAV antibody response. To investigate whether a direct viral interaction is occurring, future studies should aim to resolve at what frequency AAV is found in the genital tract and to clarify further whether AAV may infect the same HPV-positive cells in the cervix.

AB - Extensive experimental and limited epidemiologic data suggest that adeno-associated viruses (AAV) can have anti-oncogenic activity and may be protective factors for the development of cervical cancer. To examine the association between AAV-2 IgG antibodies and cervical neoplasia in Spain and Colombia, we tested for AAV-2 antibodies using an ELISA assay for 109 women with invasive cervical cancer, 100 population-based controls age-matched to the invasive cases, 77 women with carcinoma in situ (CIN III) and 100 clinic-based controls age-matched to the CIN III cases. Human papillomavirus (HPV) DNA was detected in cervical exfoliated cells by polymerase chain reaction using HPV-L1 and GP5+/6+ consensus primers. The prevalence of AAV-2 antibody titers > 100 was significantly lower in invasive cervical cancer cases than control participants. When comparing women with invasive cancer with controls or with CIN III cases, a pattern of decreasing cervical cancer risk with increasing AAV-2 titers was observed. Elevated AAV antibody titers (> 100) were inversely associated with invasive cervical cancer (OR 0.3; 95% Cl 0.1-0.7), although results were not statistically significant after controlling for HPV (OR 0.4; 95% Cl 0.1-1.6). In contrast, AAV-2 antibodies were not significantly associated with the risk of CIN III (OR 1.4; 95% Cl 0.3-6.8). These results provide supportive evidence that AAV infection may be a protective factor for the development of invasive cervical cancer. Alternatively, the lower AAV-2 seroprevalence in invasive cervical cancer cases may be due to an immunosuppressive effect of cervical cancer on AAV antibody response. To investigate whether a direct viral interaction is occurring, future studies should aim to resolve at what frequency AAV is found in the genital tract and to clarify further whether AAV may infect the same HPV-positive cells in the cervix.

KW - Adeno-associated viruses

KW - Cervical cancer

KW - Etiology

KW - HPV cofactors

UR - http://www.scopus.com/inward/record.url?scp=0035889656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035889656&partnerID=8YFLogxK

U2 - 10.1002/ijc.1496

DO - 10.1002/ijc.1496

M3 - Article

C2 - 11745438

AN - SCOPUS:0035889656

VL - 94

SP - 520

EP - 526

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -